NextBio Platform for Interpreting Genomic Data in Translational Research and Clinical Applications Passes HIPAA Audit

NextBio Platform for Interpreting Genomic Data in Translational Research and Clinical Applications Passes HIPAA Audit

SANTA CLARA, Calif.--NextBio announced today that their newly launched NextBio Clinical platform has successfully passed an independent 3rd party audit of NextBio's security controls, meeting HIPAA (the federally mandated Health Insurance Portability and Accountability Act) requirements. NextBio demonstrated the implementation of physical, technical, and administrative controls to assure the confidentiality, integrity, and availability of electronic protected health information (ePHI) in its cloud-based NextBio Clinical platform. This successful HIPAA audit enables NextBio Clinical to host protected patient information as it integrates electronic medical records (EMRs) to further the use of genomics for translational medicine and research, as well as in the clinic. NextBio offers the world's largest repository of curated and correlated molecular and clinical data.

HIPAA sets the standard for protecting personal health information (PHI) pertaining to health status, provision of health care, or payment for health care that can be linked to an individual. HIPAA interprets such information broadly to include any part of an individual's medical record or payment history.

"Security is a very high priority for us, as everyday our big data platform deals with large volumes and a wide variety of public and private molecular data from our customers and partners," said Dr. Satnam Alag, chief technology officer and vice president of engineering at NextBio. "We have made significant investments towards meeting HIPAA requirements, and NextBio is committed to a continued focus on all aspects of data security. The automated logging of access to patient information, encryption of log parameters, real-time administrator audit facilities, and encryption of ePHI are a few key features that distinguish our implementation of HIPAA."

Other important features of NextBio's HIPAA implementation include:
• Protection against any reasonably anticipated threats or hazards to the security or integrity of protected information.
• Protection against any reasonably anticipated uses or disclosures of such information that are not permitted or required by the privacy rule.
• Compliance by NextBio's workforce.
• Customized authorization of access to ePHI by client organizations.
• Real-time ePHI access report generation, enabling the client to immediately review who, what, and when ePHI was accessed; no delays requesting and waiting for logs.
• Encrypted ePHI data.
• Location of ePHI in Tier 1 Data Center using a provider that is SSAE16 Certified.

NextBio's successful passing of an independent HIPAA audit validates the instituted safeguards that enable NextBio Clinical to analyze molecular data and related clinical health information from linked EMRs. NextBio provides its products and services to clinical centers, pharmaceutical and biotechnology companies, and research institutions serving the full spectrum of life sciences research, from the laboratory to translational research to the clinic where meeting HIPAA requirements is mandatory.

About NextBio

NextBio provides a state of the art scientific platform to aggregate and interpret large quantities of molecular and other life sciences data for research and clinical applications. NextBio's platform integrates data from multiple repositories and diverse technologies by means of a unique correlation engine, which pre-computes billions of significant connections between disparate public and proprietary clinical and experimental data. This feature enables interpretation of an individual's molecular data. It also provides translational researchers the ability to look across the clinical and molecular data of entire populations for clinical trial stratification and selection, hypotheses generation, and biomarker discovery. The NextBio platform is designed for seamless integration with existing clinical and research systems. Backed by highly scalable, Big Data technology, it is capable of analyzing petabytes of data. NextBio's platform is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.

Today, NextBio is used by researchers and clinicians in over 50 top commercial and academic institutions including the University of Southern California, Sanford-Burnham Medical Research Institute, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute, Stanford University, University of California at Berkeley, Takeda and many others. To learn more about NextBio, please visit our website at http://www.nextbio.com.

Contacts

NextBio
Saeid Akhtari
President and CEO
[email protected]
or
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413
Mobile: 415-690-0210
[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.